Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone. (Q41732768)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25982919%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

title

Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25982919%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25982919%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Vincenza Conteduca

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25982919%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Orazio Caffo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25982919%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Elisabetta Petracci

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25982919%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Matteo Santoni

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25982919%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Lucia Fratino

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25982919%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

12

Ugo De Giorgi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25982919%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

3

Lisa Derosa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25982919%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

10

Francesca Maines

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25982919%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

4

Antonello Veccia

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25982919%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Vincenzo Emanuele Chiuri

6

object named as

Vincenzo Emanuele Chiuri

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25982919%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Sara Testoni

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25982919%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

language of work or name

1 reference

15 May 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25982919%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25982919%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

75

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25982919%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25982919%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

1329-1338

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25982919%20AND%20SRC:MED&resulttype=core&format=json

Metabolic syndrome as a peculiar target for management of prostate cancer patients

8 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23014

The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23014

Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23014

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23014

Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23014

Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: a prospective cohort study in patients with atherosclerotic cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23014

Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23014

Insulin and insulin-like growth factor signalling in neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23014

The insulin-like growth factor system and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23014

Metabolic sequelae associated with androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23014

Metabolic complications of androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23014

Long-term effects of androgen deprivation therapy in prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23014

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23014

Insulin sensitivity during combined androgen blockade for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23014

Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23014

Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23014

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23014

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23014

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23014

Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23014

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23014

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23014

Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23014

Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23014

Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23014

Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.23014